The burden of bleeding disorder is rapidly increasing across the globe. Developing and under developed countries are increasingly falling for bleeding disorders in the Middle East and African region. Based on the prevalence rate, hemophilia and Von Willebrand disease (VWD) are the most common bleeding disorders in the Middle East and Africa. Increasing prevalence of bleeding disorders likely to drive the growth of the market. The developing countries are providing various opportunities to the healthcare organization to come up with new affordable drugs.
The economic outlook of high income countries in the Middle East region such as Saudi Arabia, the UAE, and others is improving and is expected to support the recovery in the region. Moreover, Ministry of Health (MOH) and various other government bodies are allocating large pool of funds and coordinating health promotion programs in Saudi Arabia.
Additionally, surge in the population of Saudi Arabia strongly contributes to the increasing demand for the healthcare facilities.
Get a sample report at https://www.marketresearchfuture.com/sample_request/2743 .
Regional Analysis
MEA blood coagulants market is consist of the Middle East & African countries.
Saudi Arabia (KSA, dominates the MEA blood coagulants market with nearly 21.1% share of the Middle East & African market.
In spite of increasing demand for the treatment, the R&D sector of the Middle East and African region is not developed enough to address the upcoming health challenges.
In Saudi Arabia, the pharmaceutical industry is characterized by domestic manufacturing base and licensing agreements with branded research-based drug manufacturing firms. Moreover, the government policies are biased for domestic producers by providing them various exemptions such as, interest-free funding, neglecting import duties on raw materials, and subsidized utility charges
According to a study published in the Journal for Clinical Studies in 2014, no legal framework describing rare diseases and orphan drug research & development is present in the Middle East Countries such as Saudi Arabia, Jordan, Lebanon, and Egypt. In one of the Middle East countries, the UAE, a Biotechnology and Research Park, named as DuBiotech, has been established for improving R&D status, and to collaborate with local companies.
African region is also dependent on imported medicines and other health technologies.
Segmentation
The MEA blood coagulants market is segmented on the basis of types, indications, and by country.
On the basis of types, the market is segmented into coagulation factor and others. The coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.
On the basis of indication, the market is segmented into hemophilia, surgery, other bleeding disorders, and others. The hemophilia is further divided into hemophilia A and hemophilia B. On the basis of country, the market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of the Middle East & Africa
Browse Complete Report at https://www.marketresearchfuture.com/reports/blood-coagulants-market-2743 .
Some of the major players in this market are Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia).
The Middle East & Africa blood coagulant market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. On the other hand, there are certain factors that also hinder the growth of this market such as lack of R&D capabilities in the regions, presence of counterfeit drugs, and lack of awareness in most of the parts of developing and underdeveloped countries in the region.
The MEA blood coagulants market is segmented on the basis of types, indications, and by country.
On the basis of types, the market is segmented into coagulation factor and others. Coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.
On the basis of indication, the market is segmented into haemophilia, surgery, other bleeding disorders, and others. Haemophilia is further divided into haemophilia A and haemophilia B.
On the basis of country, the market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of Middle East & Africa.
More Inquire at https://www.marketresearchfuture.com/enquiry/2743 .
The Middle East & Africa blood coagulants market is segmented on the basis of countries into Saudi Arabia (KSA), United Arab Emirates (UAE), Qatar, Oman, Kuwait, Egypt, and rest of Middle East & Africa. Saudi Arabia account for the largest market share of the Middle East & Africa blood coagulants market by countries in 2016. The large share is majorly attributed to increasing prevalence of the haemophilia disease in this country, high usage of the expensive recombinant coagulation factors for the treatment, and high disposable income of the population, and better healthcare facilities in this country.
Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Email: akash.anand@marketresearchfuture.com
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/blood-coagulants-market-2743